Epilepsy News

The FDA has granted approval to Azurity Pharmaceuticals Inc. for its oral adjunctive therapy to treat partial seizures in adolescents and adults aged 16 years and older with epilepsy.

Treatment with ketamine significantly improved seizure occurrence related to refractory status epilepticus in both neonates and children, according to results of a study published in Neurology.

Transdermal CBD was well tolerated and safe among those with drug-resistant focal epilepsy, although no efficacy was observed compared with placebo during a 12-week treatment period, researchers reported in JAMA Network Open.

The American Academy of Neurology, along with the American Epilepsy Society and the Society for Maternal-Fetal Medicine, has provided a practice guidance update for women with epilepsy of childbearing potential.

Neurona Therapeutics has announced that a phase 1/2 clinical trial for NRTX-1001, a regenerative neural cell therapy for treatment of drug-resistant focal epilepsy in adults, is now underway.

In children with epilepsy who discontinue anti-seizure medications, the risk for seizure relapse was significantly associated with younger age at diagnosis, according to a study published in Epilepsy & Behavior.

Known for his role as a pilot in “Star Wars,” actor Greg Grunberg has traded in his flight suit to travel cross country to bring awareness to epilepsy care, treatment and patient needs.

Long-term use of Xcopri was safe and reduced seizures by more than 90% in adults with uncontrolled focal seizures, according to results of an open-label extension study published in Neurology.

Lacosamide monotherapy for the treatment of childhood epilepsy with centrotemporal spikes was well tolerated and resulted in significantly reduced seizures, according to a study published in Brain and Development.

Epilepsy was not a significant factor among adults who had been hospitalized for attempted suicide, according to a study published in the Journal of Clinical Psychiatry.